UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000008911 |
|---|---|
| Receipt number | R000010442 |
| Scientific Title | A randomized phase II study of TEC (Paclitaxel+Epirubicin+Carboplatin) therapy, TAC (Paclitaxel+Doxorubicin+Carboplatin)therapy, and ddTC (Dose-dense Paclitaxel+Carboplatin) therapy as adjuvant chemotherapy for the patients with intermediate or high risk group of endometrial carcinoma |
| Date of disclosure of the study information | 2012/10/01 |
| Last modified on | 2022/03/22 15:41:57 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2012/09/13 08:38:46 | ||
| 2 | Update | 2012/11/22 15:07:01 | Recruitment status Anticipated trial start date |
|
| 3 | Update | 2016/03/13 11:31:51 | TEL Address Address |
|
| 4 | Update | 2016/03/13 11:33:24 | Randomization unit |
|
| 5 | Update | 2016/03/13 11:34:00 | Recruitment status |
|
| 6 | Update | 2016/09/16 09:03:47 | Name of primary person or sponsor Organization |
|
| 7 | Update | 2022/03/22 15:11:08 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Organization Organization Address Address Tel |
|
| 8 | Update | 2022/03/22 15:16:21 | Date of IRB Last follow-up date Date trial data considered complete Date analysis concluded |
|
| 9 | Update | 2022/03/22 15:35:16 | Recruitment status |
|
| 10 | Update | 2022/03/22 15:41:57 | URL releasing protocol Publication of results URL related to results and publications Number of participants that the trial has enrolled Results Results Results date posted Baseline Characteristics Baseline Characteristics Participant flow Participant flow Adverse events Adverse events Outcome measures Outcome measures |
